Findings

What do systematic reviews say?

153 questions · 160 findings · 18 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 42 · 26.3%GRADE not reported 8 · 5%Very low 37 · 23.1%Low 59 · 36.9%Moderate 14 · 8.8%High 0 · 0%

Intervention not reported

Quality of life ‐ not reported · patients with myelodysplastic syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Frequency and length of hospital admissions ‐ not reported · patients with myelodysplastic syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Serious infections (requiring admission to hospital) ‐ not reported · patients with myelodysplastic syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Serious bleeding (e.g. WHO/CTCAE grade 3 (or equivalent) or above ) ‐ not reported · patients with myelodysplastic syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Red blood cell transfusion requirements (units of red blood cells per patient per month) · patients with myelodysplastic syndrome

1 finding from 1 review

Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic… 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 13 participants
Very low

Naftopidil vs silodosin (alpha‐blocker)

Sexual adverse events

Naftopidil probably leads to lower sexual adverse events compared with silodosin (alpha‐blocker) (moderate certainty).

1 finding from 1 review

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
RR 0.15 [0.06, 0.42]
4 studies · 348 participants
Moderate

Naftopidil vs silodosin (alpha‐blocker)

Urological symptom scores

1 finding from 1 review

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 652 participants
Low

Naftopidil vs silodosin (alpha‐blocker)

Quality of life

1 finding from 1 review

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 652 participants
Low

Naftopidil vs silodosin (alpha‐blocker)

Treatment withdrawal

Naftopidil showed no clear difference in treatment withdrawals for any reason compared with silodosin (alpha‐blocker) (low certainty).

1 finding from 1 review

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
RR 0.8 [0.52, 1.23]
4 studies · 659 participants
Low

Naftopidil vs silodosin (alpha‐blocker)

Cardiovascular adverse events

Naftopidil showed no clear difference in cardiovascular adverse events compared with silodosin (alpha‐blocker) (low certainty).

1 finding from 1 review

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
RR 0.98 [0.39, 2.44]
5 studies · 808 participants
Low

Index pricing vs no index pricing

Healthcare utilisation · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…

The review found no eligible studies for this question.

1 finding from 1 review

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Index pricing vs no index pricing

Health outcomes · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…

The review found no eligible studies for this question.

1 finding from 1 review

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Index pricing vs no index pricing

Adverse events · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…

The review found no eligible studies for this question.

1 finding from 1 review

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Index pricing vs no index pricing

CI: Confidence interval · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…

The review found no eligible studies for this question.

1 finding from 1 review

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Index pricing vs no index pricing

Drug use · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…

1 finding from 1 review

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Index pricing vs no index pricing

Drug prices · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…

1 finding from 1 review

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Index pricing vs no index pricing

Drug expenditure · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…

The review found no eligible studies for this question.

1 finding from 1 review

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Endoscopic cyclophotocoagulation vs the Ahmed drainage implant

Pain control · adults with refractory glaucoma

The review found no eligible studies for this question.

1 finding from 1 review

Cyclodestructive procedures for refractory glaucoma 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Micropulse vs continuous‐wave cyclophotocoagulation

Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with refractory glaucoma

1 finding from 1 review

Cyclodestructive procedures for refractory glaucoma 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 48 participants
GRADE not reported

Micropulse vs continuous‐wave cyclophotocoagulation

Mean change in the mean deviation in study eyes change from baseline 12 months postintervention · adults with refractory glaucoma

The review found no eligible studies for this question.

1 finding from 1 review

Cyclodestructive procedures for refractory glaucoma 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found